The board of directors of Baxter International Inc (NYSE:BAX) declared a quarterly dividend of USD0.22 per share of the company's common stock, it disclosed on Tuesday.
This cash dividend will be paid on 1 October 2019 to shareholders of record as of 30 August 2019.
Annually, the dividend rate is equivalent t0 USD0.88 per share of common stock, according to the company.
With products, technologies and therapies available in 100 countries, Baxter's portfolio consist of critical care, nutrition, renal, hospital as well as surgical products.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation